Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14745379 | 1.00 | APP (0.33) | APPCHRNA7CACNA1GCACNA1HCACNA1I | |
| SCHEMBL14744680 | 0.79 | MAOB (0.40) | CHRNA7 | |
| SCHEMBL14744681 | 0.79 | MAOB (0.40) | CHRNA7 | |
| SCHEMBL14746051 | 0.79 | HPGD (0.40) | APPCHRNA7CACNA1GCACNA1HCACNA1I | |
| SCHEMBL14745723 | 0.76 | CYP2A6 (0.37) | CHRNA7 | |
| SCHEMBL16440971 | 0.76 | CYP2A6 (0.37) | CHRNA7 | |
| SCHEMBL14745755 | 0.76 | CYP2A6 (0.37) | CHRNA7 | |
| SCHEMBL16972701 | 0.72 | KDM2B (0.43) | — | |
| SCHEMBL16440982 | 0.72 | PLG (0.43) | — | |
| SCHEMBL16972702 | 0.72 | KDM2B (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409905-B2 | Antibacterial compounds and methods for use | PTC THERAPEUTICS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| EP-2750504-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC Therapeutics, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033258-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | MRPL21, SLC11A2, CLPP | APP 4556/4885CHRNA7 4880/4885CACNA1G 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.